Lakewood-Amedex BiotherapeutLABT
13F holders, Q2 2026 (June 30)6holders
$3.13avg. 13F price*
At the end of Q2 2026, 6 institutions reported holding Lakewood-Amedex Biotherapeut (LABT) in their 13F filings. The largest holders were Marex Group Ltd ($151K), HRT Financial LP ($140K) and UBS Group AG ($13K).
- Company
- Lakewood-Amedex Biotherapeut
- CUSIP
- 51255A201
- Latest filing quarter
- Q2 2026
Total Exit/New Position Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 6 | $307K |
| Exits | 0 | $0 |
Ownership 6 holders
| Marex Group Ltd | 0.00% | New | 48,167 | $151K |
| HRT Financial LP | 0.00% | New | 44,782 | $140K |
| UBS Group AG | 0.00% | New | 4,098 | $13K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 624 | $2K |
| Osaic Holdings, Inc. | 0.00% | New | 138 | $433 |
| Blue Trust, Inc. | 0.00% | New | 11 | $35 |
"% of holder's portfolio" is LABT's weight in each manager's 13F, not the share of Lakewood-Amedex Biotherapeut the manager owns.